Real-world effectiveness of MBA-VN vaccine against mpox, a test-negative case-control study
Our study provides context-specific evidence on the effectiveness of a single MVA-BN vaccine dose against symptomatic mpox in a real-world setting. Vaccine effectiveness estimates varied depending on adjustment strategy, highlighting the importance of accounting for epidemiological weeks to avoid overestimation.
Authors
- Oleguer Parés‐Badell (ORCID: https://orcid.org/0000-0003-2568-7550)
- Martí Vivet-Escalé (ORCID: https://orcid.org/0000-0002-0781-3288)
- Laia Pinós (ORCID: https://orcid.org/0000-0002-0254-0209)
- Patricia Álvarez‐López (ORCID: https://orcid.org/0000-0003-4227-1987)
- Patricia Nadal‐Barón (ORCID: https://orcid.org/0000-0002-2656-2656)
- Andrés Antón (ORCID: https://orcid.org/0000-0002-1476-0815)
- Jorge García (ORCID: https://orcid.org/0000-0003-4986-6094)
- Blanca Borràs-Bermejo (ORCID: https://orcid.org/0000-0003-4111-5632)
- Arnau Peñalver-Piñol (ORCID: https://orcid.org/0000-0003-3524-9140)
- J. Ordas Martínez
- Pía Escobar-Ziede
- Jose-Ángel Rodrigo-Pendás
Institutions
- Vall d'Hebron Institut de Recerca (ES)
- Vall d'Hebron Hospital Universitari (ES)
Publication Details
- Journal
- Vaccine
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127295
- Primary Topic
- Poxvirus research and outbreaks
- Type
- article
- Field-Weighted Citation Impact
- 0.00